enGene (NASDAQ:ENGN) CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive bladder cancer (NMIBC). Speaking at a Barclays event moderated by Senior Biotech Analyst Etzer Darout, Cooper described 2026 as an “exciting time” for the company [...]
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference
